Surgical-imaging Research on Obesity (SIRO)
Surgical-imaging Combined Research on Obesity
1 other identifier
observational
200
1 country
1
Brief Summary
The global obesity epidemic is well established, and is an important public health issue. The previous researches had applied the clues that obesity is a kind of systemic disease. The investigators hypothesized that a serious alteration of the body systems will occur after bariatric surgery, which may shed light on the mechanisms of obesity. Thus, the research aims to combine the imaging and surgery to investigate the alterations of the body that induced by obese and alterations after surgery.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2023
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2023
CompletedFirst Submitted
Initial submission to the registry
February 6, 2024
CompletedFirst Posted
Study publicly available on registry
February 20, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 1, 2028
March 15, 2024
March 1, 2024
3.8 years
February 6, 2024
March 13, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Imaging parameters of obesity
Brain cortical thickness in millimeter
baseline, 6th month
Imaging parameters of obesity
The volume of left ventricle in cubic millimeter
baseline, 6th month
Imaging parameters of obesity
Fat fraction of liver (dividing the in-phase fat attenuation signal by the out-phase fat attenuation signal)
baseline, 6th month
Secondary Outcomes (4)
Neurotransmitter, inflammatory factors and hormones related to obesity in blood sample
baseline, 6th month
Neurotransmitter, inflammatory factors and hormones relating to obesity in blood sample
baseline, 6th month
Neurotransmitter, inflammatory factors and hormones related to obesity in blood sample
baseline, 6th month
Genetic information from venous blood sample, biopsied liver tissue, biopsied fat tissue, and gastric tissue
baseline
Study Arms (2)
Obesity
Non-intervention
Healthy control
Non-intervention
Eligibility Criteria
Aged between 18 and 65, regardless of gender. Initially diagnosed as obesity (BMI\>28) and plan to undergo bariatric surgery.
You may qualify if:
- Meeting the obesity criteria (BMI \> 28); 2) Meeting the indications for bariatric surgery, planning to undergo surgery for the first time; 3) Age between 18-65 years old, no gender restrictions; 4) Right-handed, of Han ethnicity; 5) Informed consent to the study, willing to cooperate with the research, and able to sign an informed consent form.
- Healthy volunteers with a BMI between 18.5-23.9;
- Age between 18-65 years old, no gender restrictions;
- Right-handed, of Han ethnicity;
- Informed consent to the study, willing to cooperate with the research, and able to sign an informed consent form.
You may not qualify if:
- Secondary obesity caused by other organic diseases or medication (such as hormone use, etc.);
- Unable to undergo surgery as planned;
- Pregnant or breastfeeding;
- Low cognitive ability and incapable of cooperating with the study;
- Eating disorders;
- Alcohol or drug dependence;
- Meeting the criteria for organic mental disorders, severe mental disorders (schizophrenia, etc.), or other serious mental illnesses requiring clinical intervention;
- Contraindications for MR scanning (pacemakers, cochlear implants, metal objects in the body, claustrophobia, weight exceeding the machine's load limit, etc.);
- History of neurological organic diseases (brain tumors, epilepsy, cerebrovascular accidents, severe head trauma, etc.);
- History of congenital heart disease (myocardial infarction, severe arrhythmias, heart failure, cardiomyopathy, rheumatic heart disease, congenital heart disease, etc.);
- Severe liver, kidney, lung, digestive dysfunction, endocrine, and blood system diseases;
- Active infections within the last two weeks (fever, upper respiratory infection, acute gastroenteritis, etc.);
- Use of drugs affecting the nervous system or psychotropic drugs within the last six months.
- The same criteria as points 3) to 13) above.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, 221000, China
Related Publications (5)
Tutor AW, Lavie CJ, Kachur S, Milani RV, Ventura HO. Updates on obesity and the obesity paradox in cardiovascular diseases. Prog Cardiovasc Dis. 2023 May-Jun;78:2-10. doi: 10.1016/j.pcad.2022.11.013. Epub 2022 Dec 5.
PMID: 36481212BACKGROUNDMalone JI, Hansen BC. Does obesity cause type 2 diabetes mellitus (T2DM)? Or is it the opposite? Pediatr Diabetes. 2019 Feb;20(1):5-9. doi: 10.1111/pedi.12787. Epub 2018 Nov 5.
PMID: 30311716BACKGROUNDSchwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Central nervous system control of food intake. Nature. 2000 Apr 6;404(6778):661-71. doi: 10.1038/35007534.
PMID: 10766253BACKGROUNDRaji CA, Meysami S, Hashemi S, Garg S, Akbari N, Gouda A, Chodakiewitz YG, Nguyen TD, Niotis K, Merrill DA, Attariwala R. Visceral and Subcutaneous Abdominal Fat Predict Brain Volume Loss at Midlife in 10,001 Individuals. Aging Dis. 2024 Aug 1;15(4):1831-1842. doi: 10.14336/AD.2023.0820.
PMID: 37728587BACKGROUNDGutierrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases. Int J Mol Sci. 2021 Oct 27;22(21):11629. doi: 10.3390/ijms222111629.
PMID: 34769060BACKGROUND
Biospecimen
Venous blood samples, biopsied liver tissue, biopsied fat tissue, gastric tissue
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 6, 2024
First Posted
February 20, 2024
Study Start
March 1, 2023
Primary Completion (Estimated)
December 1, 2026
Study Completion (Estimated)
December 1, 2028
Last Updated
March 15, 2024
Record last verified: 2024-03